Tvardi Therapeutics is trading 9.43% up at $1.16 in pre-market after announcing positive preclinical data for its STAT3 inhibitors in ulcerative colitis. - TTI-101 reached approximately eight times higher concentrations in colon tissue and prevented polyps and adenocarcinomas in a mouse model. - The publication was announced September 24, 2026, and likely drove a rebound after shares fell 19.70% that session; broader markets were only modestly higher. - TTI-109 clinical development remains dependent on IND clearance and additional funding.